Is cancer incidence modified by SGLT2 inhibitors?
One of the most important achievements of diabetology in the second decade of the 21st century is undoubtedly the introduction of sodium-glucose cotransporter (SGLT2) inhibitors into clinical practice as a new class of glucose-lowering agents for type 2 diabetes. In addition to the glucosuria induce...
| Published in: | Сахарный диабет |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2019-10-01
|
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/10119 |